AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 779998
Drug: Parenteral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral cholera vaccine
Trial: 30543266
Drug: Ultrasound-guided hypertonic
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hypertonic dextrose (20%) injection
Trial: 30543266
Drug: 5% normal
RxNorm normalized name: dextrose 5%-0.225% normal saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% normal saline injection
Trial: 28454576
Drug: Permethrin-fipronil combination
RxNorm normalized name: fipronil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin-fipronil combination (Effitix®) - treated three times every 4 weeks with a spot-on containing 54.5% permethrin and 6.1% fipronil.
Trial: 28454576
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Control group B).
Trial: 21707928
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once a day for 12 weeks
Trial: 16961291
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a combination of 10% glucose, Vitamin C, and Inosine
Trial: 9412897
Drug: Calcium salts
RxNorm normalized name: lonazolac calcium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium salts administration after CPB
Trial: 12356634
Drug: Calcium administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium administration
Trial: 3108105
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Sorbinil daily for 1 year
Trial: 31907074
Drug: TANDEM intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TANDEM intervention (tailored cognitive behavioural approach) delivered weekly for 6-8 weeks by trained respiratory healthcare professionals
Trial: 30031660
Drug: DXA-derived visceral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DXA-derived visceral adipose tissue measures (VAT, VAT/Total fat, visceral-to-subcutaneous fat)
Trial: 24269077
Drug: Intensive, individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive, individual dietary counseling (1 hour per week) and daily oral nutritional supplement (2531 kJ, 33.8 g protein, 2.2 g EPA)
Trial: 17276552
Drug: Two-dose hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose hepatitis B immunisation (20 microg HBsAg doses 6 months apart)
Trial: 17276552
Drug: Three-dose hepatitis
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose hepatitis B immunisation (10 microg HBsAg doses at 0, 1, 6 months)
Trial: 12677149
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg/d) for 12 weeks postoperatively
Trial: 1615132
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (0, 25, 50, 100 micrograms/70 kg)
Trial: 6496915
Drug: Bupivacaine during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine during intravenous regional analgesia
Trial: 3514155
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05 percent ointment
Trial: 3514155
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate 0.05 percent ointment
Trial: 24084921
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus MPA (0.625 mg/d CEE + 2.5 mg/d MPA)
Trial: 24084921
Drug: CEE alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE alone (0.625 mg/d CEE)
Trial: 16618262
Drug: Acetaminophen 250
RxNorm normalized name: acetaminophen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 250 mg, Aspirin 250 mg, Caffeine 65 mg per tablet (AAC)
Trial: 16618262
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg per tablet (IB)
Trial: 7582397
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol treatment
Trial: 9428032
Drug: L‐mode (non-linear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐mode (non-linear amplification mode)
Trial: 1403041
Drug: Etoposide with
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide with high-dose cyclosporine (CsA)
Trial: 29124831
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate
Trial: 31730666
Drug: Topical lactic
RxNorm normalized name: lactic acid Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lactic acid gel
Trial: 31730666
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole antibiotic
Trial: 27317968
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (150mg daily)
Trial: 27317968
Drug: Diclofenac (150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (150mg daily)
Trial: 20438378
Drug: Initial HIV
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial HIV therapy strategies (specific strategies not detailed in the abstract)
Trial: 12807526
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg eletriptan (E40)
Trial: 12807526
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg eletriptan (E80)
Trial: 10806014
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment effects on ischaemia
Trial: 1672389
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination of children aged between 0 and 4 years
Trial: 1672389
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination of children between 1 and 9 months old
Trial: 1672389
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination regimens
Trial: 6141797
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (Normoc)
Trial: 6141797
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (commercially available)
Trial: 28826313
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (1,200 mg daily for 8 weeks)
Trial: 26208048
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg per day for the first week, followed by 40 mg per day from weeks 2 through 12
Trial: 23841970
Drug: Horseback riding
RxNorm normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Horseback riding therapy (HBRT) plus conventional physiotherapy for 16 weeks
Trial: 23841970
Drug: Horseback riding
RxNorm normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Horseback riding therapy (HBRT) plus conventional physiotherapy
Trial: 7525661
Drug: Intravenous FK506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous FK506 (20 micrograms/kg x 4 hours)
Trial: 7525661
Drug: Oral FK506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral FK506 (80 micrograms/kg)
Trial: 3310632
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g four times daily (group A, n = 131)
Trial: 3310632
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g twice daily (group B, n = 128)
Trial: 3310632
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g four times daily (group A)
Trial: 3310632
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g twice daily (group B)
Trial: 27187435
Drug: Brazilian green
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian green propolis (900 mg/day)
Trial: 20609003
Drug: VAAM ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAAM ingestion (3000 mg/day)
Trial: 18726947
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of oral desmopressin
Trial: 8739022
Drug: CGP 36,742
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 36,742 (600 mg single oral dose)
Trial: 2127791
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alfa‐2a (6 million units thrice weekly for 1 month, followed by 3 million units for 3 months, and 1 million units maintenance therapy for 8 months)
Trial: 2127791
Drug: Retrospective analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective analysis of patients' sera for antibody to hepatitis C virus
Trial: 31142242
Drug: Hydrocortisone monotherapy
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone monotherapy
Trial: 25533997
Drug: Fluoxetine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (single dose)
Trial: 21479856
Drug: CEUS (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEUS (all doses combined)
Trial: 18467147
Drug: Skin infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin infiltration with 20 ml of ropivacaine 0.75% (Gr R)
Trial: 18467147
Drug: Skin infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin infiltration with 20 ml of 0.9% saline solution (Gr P)
Trial: 16204359
Drug: Theophylline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (1 mg/kg IV for three days)
Trial: 7824566
Drug: 0.30% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.30% menthol solution
Trial: 7824566
Drug: 0.03% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% menthol solution
Trial: 26201312
Drug: VPZ 5
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPZ 5 mg
Trial: 26201312
Drug: VPZ 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPZ 10 mg
Trial: 26201312
Drug: VPZ 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPZ 20 mg
Trial: 26201312
Drug: VPZ 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPZ 40 mg
Trial: 24213913
Drug: Guideline-adherent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-adherent therapy
Trial: 24213913
Drug: Non-guideline-adherent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-guideline-adherent therapy
Trial: 24213913
Drug: Guideline-recommended combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended combination of amoxicillin-gentamicin
Trial: 24213913
Drug: Guideline-adherent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-adherent therapy for patients with a catheter
Trial: 19043984
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy with allergens absorbed on calcium phosphate
Trial: 19043984
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy with allergens absorbed on aluminium hydroxide
Trial: 8694325
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 1 microgram/mL at thoracic level (Ts)
Trial: 8694325
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 1 microgram/mL at lumbar level (Ls)
Trial: 8694325
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 1 microgram/mL combined with bupivacaine 1 mg/mL at thoracic level (Tsb)
Trial: 8694325
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion (all groups)
Trial: 28482858
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction group (33% and 50% dose reduction of biologics)
Trial: 28482858
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no dose reduction)
Trial: 28482858
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction group
Trial: 26185017
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of ACE-inhibitors
Trial: 26185017
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of diuretics, insulin, and digitalis
Trial: 26185017
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diuretic and ACE-inhibitor
Trial: 23480640
Drug: Twice-daily darunavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Trial: 20854382
Drug: Lisinopril 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20, 40 and 60 mg daily
Trial: 16982943
Drug: Bosentan (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (62.5 mg for 1 day and 125 mg for the following 2 days)
Trial: 15339556
Drug: Cinobufacini injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinobufacini injection
Trial: 10726719
Drug: Per 2/Ind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per 2/Ind 0.625 mg
Trial: 10726719
Drug: Per 4/Ind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per 4/Ind 1.25 mg
Trial: 10726719
Drug: Per 8/Ind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per 8/Ind 2.5 mg
Trial: 10726719
Drug: Per 0/Ind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per 0/Ind 1.25 mg
Trial: 10726719
Drug: Per 2/Ind
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per 2/Ind 1.25 mg
Trial: 10726719
Drug: Other doses
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other doses (0-4.6%)
Trial: 1485136
Drug: Chondroitin sulfate
RxNorm normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulfate (4 capsules/day)
Trial: 6585371
Drug: Tetracycline therapy
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline therapy for 2 weeks
Trial: 6585371
Drug: Metronidazole therapy
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole therapy for 1 week
Trial: 6585371
Drug: Combined systemic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined systemic antimicrobial therapy and mechanical plaque control
Trial: 31237183
Drug: Tryptophan (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptophan (1000 mg/day)
Trial: 31237183
Drug: Placebo (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1000 mg/day)
Trial: 22716975
Drug: Zidovudine for
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine for 6 weeks plus three doses of nevirapine during the first 8 days of life (two-drug group)
Trial: 22716975
Drug: Zidovudine for
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine for 6 weeks plus nelfinavir and lamivudine for 2 weeks (three-drug group)
Trial: 8676931
Drug: Three-drug group
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug group
Trial: 17683996
Drug: Intravenous clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clodronate (900 mg, n = 33)
Trial: 11880863
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg p.o., fast release form)
Trial: 7000598
Drug: Chlorpropamide treatment
RxNorm normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpropamide treatment in insulin dependent diabetics
Trial: 7000598
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no chlorpropamide treatment)
Trial: 7000598
Drug: Non-insulin dependent
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin dependent diabetics
Trial: 7000598
Drug: Non-insulin dependent
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-insulin dependent diabetics with family history
Trial: 23599979
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil at 1 f.Lg/L (group A)
Trial: 23599979
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil at 2 f.Lg/L (group B)
Trial: 23599979
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil at 3 f.Lg/L (group C)
Trial: 23599979
Drug: Target controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil at 4 f.Lg/L (group D)
Trial: 21398087
Drug: Subcutaneous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ketamine infusion (0.1, 0.15, or 0.2 mg/kg/h)
Trial: 21398087
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine (300 mg/day, interquartile range 240-382.5)
Trial: 18608549
Drug: 50 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/day soy protein containing 164 mg isoflavones
Trial: 16395099
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels > or = 40 mg/dL
Trial: 16395099
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels > or = 120 mg/dL
Trial: 16395099
Drug: C-LRTI with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-LRTI with CRP levels > or = 40 mg/dL
Trial: 9226527
Drug: Nizatidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (10 mg/kg/day in two doses for 8 weeks)
Trial: 8434246
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg daily
Trial: 8434246
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 400 mg daily
Trial: 2885356
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg three times a day)
Trial: 2885356
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg and 40 mg)
Trial: 22435439
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 220 mg twice daily for 90 days
Trial: 11112236
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (unfractionated heparin or low‐molecular‐weight heparin (reviparin) and a coumarin derivative)
Trial: 1350237
Drug: Pramipexole 0.1
RxNorm normalized name: pramipexole 0.125 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.1 mg
Trial: 1350237
Drug: Pramipexole 0.2
RxNorm normalized name: pramipexole 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.2 mg
Trial: 1350237
Drug: Pramipexole 0.3
RxNorm normalized name: pramipexole 0.375 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.3 mg
Trial: 3676230
Drug: Diet L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet L (50 g lactitol/d)
Trial: 3676230
Drug: Diet S
RxNorm normalized name: Chewable Diet Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet S (49 g saccharose/d)